SynthesisBMC public health2025
MPOX outbreak in Africa: the urgent need for local manufacturing of the vaccine and decolonized health systems.
Synthesis in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mpox vaccine acceptance and uptake in Africa: a systematic review and meta-analysis.BMC global and public health · 2026Pooled it
- Healthcare inequity in mpox testing intention: A socioeconomic status-stratified path analysis of medical discrimination and distrust among men who have sex with men in China.Global health research and policy · 2026Article
- Mpox Outbreak in the East Africa Region: Current Status, Containment Measures, Challenges, and Future Direction.Public health challenges · 2026Review
- Correction: MPOX outbreak in Africa: the urgent need for local manufacturing of the vaccine and decolonized health systems.BMC public health · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe resurgence of MPOX (formerly known as Monkeypox) across African countries has highlighted longstanding deficiencies in epidemic preparedness, vaccine access, and healthcare infrastructure on the continent. Despite bearing a significant disease burden, African nations continue to face delays in vaccine acquisition and distribution, reflecting more profound structural and historical inequities.
methodsThis systematic review synthesizes literature published between 2016 and 2024, including peer-reviewed articles, policy documents, and institutional reports. The review aims to explore the dynamics of MPOX outbreaks in Africa, patterns of vaccine inequity, and the systemic limitations that hinder local response capacity. A narrative synthesis approach was employed to analyze data relating to vaccine access, production capacity, regulatory environments, and structural determinants of health.
resultsThe findings reveal Africa's continued dependency on external vaccine sources, shaped by colonial legacies and weak local pharmaceutical systems. During the 2022 global MPOX outbreak, high-income countries swiftly secured vaccine supplies, while African nations experienced significant delays despite high transmission rates. Although efforts to establish local manufacturing are emerging, they are constrained by limited infrastructure, fragmented regulatory systems, shortages of skilled workers, and restrictive intellectual property regimes. Furthermore, the review identifies a need for harmonized regulatory frameworks and sustainable investment in regional manufacturing capabilities.
conclusionAddressing MPOX and future health threats in Africa demands a shift toward decolonized health systems that emphasize South-South collaboration, indigenous knowledge, and local ownership. Strategic interventions, such as regulatory harmonization, equitable technology transfer, and capacity-building, are essential to reduce external dependency. Coordinated short-term actions and long-term investments are crucial for fostering resilient, self-sustaining health systems that can respond effectively to emerging infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.